The Missouri Division of Cannabis Regulation (DCR) has recently taken a significant step in the cannabis industry by issuing a recall of more than 62,000 cannabis products manufactured by Delta Extraction, LLC. The reason behind this recall lies in the fact that these products were not being compliantly tracked in the statewide track and trace system known as METRC. This failure to adhere to tracking protocols created a situation where the DCR could not verify the origins of these products – whether they were sourced from marijuana cultivated within Missouri and had undergone the necessary testing procedures.

The scope of this recall encompasses a wide range of cannabis-infused products, including tinctures, vape cartridges, gel capsules, tablets, and other similar items. To ensure public safety, the DCR has strongly recommended that consumers who have purchased any of these affected products take appropriate action. They can either discard these items or return them to the dispensary where they were originally purchased. Importantly, the DCR has reassured consumers that these returns will not impact their established monthly purchase limits, providing a degree of comfort to those affected.

The DCR has been proactive in promoting awareness among consumers regarding the risks associated with marijuana products that have not been appropriately tracked in the METRC system. By urging consumers to follow the prescribed disposal or return procedures, the DCR is attempting to safeguard the well-being of the public.

Additionally, the DCR has emphasized the significance of reporting any adverse reactions related to the use of these products. They have provided channels for reporting such reactions, including email and an online complaint form, underlining their commitment to ensuring consumer safety.

The context leading up to this recall involves a lengthy hearing at the Administrative Hearing Commission. During this hearing, Delta Extraction challenged the immediate suspension of its license by the Missouri Department of Health and Senior Services (DHSS). The suspension followed the discovery that Delta Extraction had incorporated out-of-state hemp-derived THCa into its marijuana products. THCa is the non-psychoactive compound in marijuana that converts into THC when heated, producing the characteristic “high.”

Delta Extraction’s representative, Jack Maritz, asserted that the distillation process allowed for the utilization of out-of-state hemp-derived THCa. The company’s position was based on previous state regulations that seemed to permit this practice. However, the state counterargued that recent regulations had clarified the prohibition of such practices. The outcome of the hearing remains pending, as the Administrative Hearing Commission has yet to decide on the reinstatement of Delta Extraction’s license.

Rachael Herndon, Delta’s chief operational officer, highlighted the adverse effects of the license suspension on the company’s reputation and financial standing. She stated, “Our reputation was damaged, and we had over $10 million in product on our site immediately locked up.”

This recall serves as a poignant reminder to both cannabis producers and consumers about the ever-evolving landscape of rules and regulations in the cannabis industry. The rapid shifts in policies underline the necessity for all stakeholders – including manufacturers, dispensaries, patients, and consumers – to remain diligently informed about the most current guidelines and procedures. By staying up-to-date, the industry can collectively work towards maintaining high standards of safety and compliance.

Source: Beardbrospharms

EXPLORE MORE NEWS

Major Corporations Investing in Cannabis

As cannabis legalization continues to spread across the country, major corporations are increasingly taking notice and investing in the industry. In April of 2023, a major beverage company announced a $100 million investment in a cannabis-infused drink startup, signaling the growing trend of large corporations entering the cannabis space.

Republican Resistance Blocks Medical Cannabis Legalization Push in North Carolina

Republican resistance has effectively halted the push for medical cannabis legalization in North Carolina. State House Speaker Tim Moore believes that the opposition from Republican lawmakers has doomed the prospects of passing the Compassionate Care Act in 2023. Despite the state Senate’s approval of the bill, which aimed to provide access to smokable flower for patients with 15 qualifying medical conditions in a tightly regulated market, the House took no further action beyond a committee hearing.

NCAA Medical Committee Calls for End to Cannabis Penalties for College Athletes

In a significant and up-to-date policy shift, the NCAA (National Collegiate Athletic Association) medical committee has recommended that college athletes should no longer face penalties for using cannabis. This progressive stance reflects the evolving landscape of cannabis regulations across the United States. The committee has firmly asserted that drug testing efforts should be redirected towards detecting performance-enhancing substances, leaving cannabis use without punitive measures. This recommendation comes after the committee conducted a thorough review of existing policies and solicited input from member organizations. It anticipates that the final decision on this matter will be made in the fall, following consultations and legislative processes within each of the NCAA’s governing bodies.

South Dakota’s Medical Cannabis Program Surpasses Expectations, Raises Concerns

South Dakota’s foray into medical cannabis has far exceeded its initial projections, with the issuance of medical cannabis cards doubling the expected numbers. Since the program’s launch in 2021, the South Dakota Department of Health has issued approximately 11,500 medical cannabis cards, significantly surpassing the original projection of 6,000 cards to be issued by 2024.

Newsletter